Since then, there have been several immunotherapy drugs and immunotherapy technologies developed every year. Two such drugs are nivolumab and pembrolizumab. Both are FDA approved for the treatment of ...

Immunotherapy combinations based on nivolumab entail lower costs for grade 3/4 adverse events than those using pembrolizumab, a finding that could inform treatment decisions.

References: van Rijssen L, Nagtegaal IEC, Ploos van Amstel FK, et al. Safety of accelerated infusion of nivolumab and pembrolizumab. Eur J Cancer.Published online March 21, 2025. doi:10.1016/j ...

CHICAGO — An alternative dosing strategy of pembrolizumab and nivolumab may substantially reduce pharmaceutical costs without compromising efficacy in treating various cancers, according to ...

The monthly incremental cost per survivor relative to sunitinib for nivolumab plus ipilimumab decreased over time from $90,035 for 12 months to $18,881 for 48 months. Compared with pembrolizumab ...

The pivotal CheckMate 067 trial, which evaluated the combination of nivolumab, an anti–PD-1 agent like pembrolizumab, and ipilimumab against either drug alone in patients with melanoma, reported ...

The FDA narrowed the indications for pembrolizumab (Keytruda) and nivolumab (Opdivo) in gastric, gastroesophageal junction (GEJ), and esophageal cancers, according to letters sent to the ...